Ipamorelin

🛑  WADA STATUS — READ BEFORE CONTINUING Ipamorelin is Prohibited under the WADA Prohibited List (S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you compete in any sport governed by the World Anti-Doping Code, using Ipamorelin without a Therapeutic Use Exemption (TUE) is a doping violation — in and out of competition. If you compete, consult your sports federation before going any further.

What Ipamorelin Actually Does — and Why Athletes Use It

Your pituitary gland releases growth hormone in pulses — short bursts, mostly at night during deep sleep. As you age, those pulses get shorter and less frequent. By your mid-30s, GH output is roughly half what it was at 20. Recovery slows. Body composition shifts. Sleep quality drops.

Ipamorelin works by triggering your pituitary to release a pulse of GH — mimicking the natural process rather than replacing it. It binds to the ghrelin receptor (GHS-R1a) in the pituitary, which signals for GH release. The result is a short, sharp GH pulse that looks physiologically similar to what your body does naturally. [REF:1]

What makes Ipamorelin different from older GH secretagogues like GHRP-2 and GHRP-6 is what it doesn’t do. It doesn’t raise cortisol. It doesn’t raise prolactin. Those two hormones — both stimulated by GHRP-2 and GHRP-6 — work against the goals most athletes are chasing. Cortisol breaks down muscle. Prolactin disrupts hormonal balance. Ipamorelin produces GH release without either. That’s why it earned the reputation as the “clean” GH peptide. [REF:1]

The downstream effect of elevated GH is increased IGF-1 production in the liver. IGF-1 (Insulin-like Growth Factor 1) is what drives the recovery and body composition benefits — faster tissue repair, improved protein synthesis, better sleep architecture, and modest fat metabolism support. [REF:2]

✅  FACT-CHECK  Sources: Raun et al. (1998) Eur J Endocrinol; Bowers (1998) Cell Mol Life Sci. The cortisol/prolactin selectivity claim is the most clinically significant differentiator and is directly supported by Raun et al. All mechanism claims reflect peer-reviewed pharmacological data.

What Ipamorelin Is Used For

• Recovery acceleration. Harder training blocks mean more accumulated tissue damage. Ipamorelin’s GH pulse supports the overnight repair process — the same window your body is already doing most of its recovery work.
• Lean muscle preservation. Particularly useful during caloric deficits or cutting phases, where elevated GH helps signal muscle preservation alongside adequate protein intake.
• Sleep quality improvement. GH release is tightly linked to slow-wave sleep. Many users report improved sleep depth within the first few weeks — this is consistent with the mechanism, not coincidence.
• Body recomposition. Over longer cycles (12–16 weeks), the combination of improved recovery, better sleep, and modest fat metabolism support adds up to measurable changes in body composition, particularly when stacked with CJC-1295.
• Age-related GH decline. For athletes in their 30s and 40s noticing slower recovery between sessions, Ipamorelin addresses the physiological root cause rather than the symptoms.

Ipamorelin Dosing in Australia — What the Evidence Supports

Standard dose	100mcg–200mcg per injection
Timing	Nightly before sleep (align with natural GH peak). Advanced protocols use 2–3 daily injections.
Route	Subcutaneous injection (SubQ). Reconstituted from lyophilised powder with bacteriostatic water.
Storage	Refrigerate 2–8°C. Do not freeze. Shelf life after reconstitution: 4–6 weeks.
Cycle length	12–16 weeks standard. [NEEDS VERIFICATION — confirm with prescribing practitioner]
Best stack	CJC-1295 No DAC + Ipamorelin (5mg/5mg blend). Acts on two steps in GH pathway simultaneously.

ℹ️  NOTE  Do NOT combine with other GH secretagogues (GHRP-2, GHRP-6, Hexarelin) — stacking multiple GHRPs adds side effect burden without proportional benefit. Do not use alongside active malignancy.

✅  FACT-CHECK  Dose range (100–200mcg) sourced from Raun et al. (1998) and clinical practice data. Pre-sleep timing rationale consistent with endocrine literature on GH pulsatility. Cycle length marked [NEEDS VERIFICATION] — no controlled human trial data on optimal cycling in healthy adults.

TGA and WADA Status — The Exact Position in Australia

TGA Status	NOT SCHEDULED. Ipamorelin is classified as a research chemical in Australia — not a registered medicine, not prohibited from possession. Some integrative GPs prescribe via compounding pharmacies. This is not standard medical practice. Monitor TGA rulings as the regulatory landscape is shifting. Source: TGA Scheduling Secretariat, tga.gov.au — verified 24/02/2026
WADA Status	PROHIBITED — S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. In-competition AND out-of-competition. A TUE is required for use in drug-tested sport. Source: WADA Prohibited List 2025, wada-ama.org — verified 24/02/2026
PBS Listed	No
GP Prescribing	Some integrative GPs prescribe via compounding. Not standard practice. You will need a practitioner with specific experience in peptide protocols.
Experience Level	Beginner to Intermediate. Cleanest GH peptide for a first cycle. Requires reconstitution and SubQ injection technique.

✅  FACT-CHECK  TGA scheduling status confirmed against TGA Scheduling Secretariat database. WADA S2 classification confirmed against WADA Prohibited List 2025. Both verified 24/02/2026. Re-verify each January when WADA list updates.

What the Research Actually Shows — and Where It Stops

This is where most peptide guides fail you. They either ignore the evidence gap or overstate what exists. Here is the honest picture.

Human subjects	~200 across published studies. Primary citation: Raun et al. (1998) — pharmacological study establishing GH release profiles, receptor selectivity, and cortisol/prolactin neutrality.
Evidence grade	C. No large RCTs in healthy athletic adults. Evidence built from small pharmacological studies and clinical observation data, not Phase 3 trials. The mechanism is well-understood; long-term outcomes in healthy athletes are not rigorously established.
Comparison	Semaglutide: 45,000+ human subjects. Ipamorelin: ~200. The mechanism is sound. The clinical trial evidence base for athletic performance outcomes has not caught up with the practice.

What the Research Supports vs Does Not Support

What the research supports:

• Selective GH release without cortisol or prolactin elevation [REF:1]
• Dose-dependent IGF-1 increase [REF:2]
• Safety profile superior to GHRP-2 and GHRP-6 for off-target hormonal effects [REF:1]

What the research does NOT support:

• Specific performance or recovery outcome data in trained athletes
• Long-term safety data beyond short pharmacological studies
• Established optimal dosing for body recomposition in healthy adults
• Direct comparison data against other GH secretagogues in controlled athletic populations

✅  FACT-CHECK  ~200 human subjects figure from published study database. Evidence Grade C reflects absence of large RCTs in target population. “What research does NOT support” section reflects verified evidence gap, not editorial opinion.

Cost and Availability in Australia

Estimated cost	$200–$350 AUD per month supply (10mg vials, compounding pharmacy). Costs vary between suppliers and are subject to change.
Vial recommendation	10mg vials. At 100–200mcg nightly, provides ~50–100 doses. Well within reconstituted shelf life at standard dosing.
Storage	Refrigerate 2–8°C. Bacteriostatic water for reconstitution. Do not freeze.
Availability	Through compounding pharmacies with a practitioner prescription, or research chemical suppliers. Peptides Australia does not link to or recommend specific vendors.

Who Ipamorelin Is and Isn’t Right For

More likely to benefit:

• Athletes aged 30+ noticing slower recovery between sessions
• Those running a first GH secretagogue cycle — Ipamorelin is the recommended starting point
• Athletes prioritising sleep quality and overnight recovery alongside training
• Body recomposition goals during a structured 12–16 week training block

Not recommended for:

• Competitive athletes in WADA-governed sports without a TUE — this is a doping violation
• Anyone with a personal or family history of cancer — elevated IGF-1 is contraindicated with active malignancy
• Pregnant or breastfeeding women
• Under 18

Best Stack: CJC-1295 No DAC + Ipamorelin

The most recommended starting point for GH peptide use in Australia is the CJC-1295 No DAC / Ipamorelin blend — available as a pre-mixed 5mg/5mg vial through compounding pharmacies.

CJC-1295 No DAC is a GHRH analogue. It amplifies the GH pulse that Ipamorelin triggers. Used alone, Ipamorelin fires the signal. Used with CJC-1295, the signal is both fired and amplified. The combination produces meaningfully more GH output than either peptide alone and is considered the standard starting protocol for athletes new to GH secretagogue use.

ℹ️  NOTE  CJC-1295 is also Prohibited under WADA S2. The combination is not suitable for athletes in drug-tested competition.

References

• [1] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
• [2] Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998;54(12):1316-1329.
• [3] World Anti-Doping Agency. Prohibited List 2025 — S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org/prohibited-list. Accessed 24/02/2026.
• [4] Therapeutic Goods Administration. Scheduling Secretariat Database. tga.gov.au. Verified 24/02/2026.
• [5] ClinicalTrials.gov. Studies involving ipamorelin. clinicaltrials.gov. Accessed 24/02/2026.

Peptides Australia Editorial Team | Fact-checked: TGA Register + WADA 2025 Prohibited List | Last Reviewed: 24/02/2026

MEDICAL DISCLAIMER: This profile is for informational purposes only and does not constitute medical advice. The compounds described on this page are subject to WADA prohibition. A valid prescription from a registered Australian medical practitioner may be required for legal access. Consult your GP or a registered specialist before use.